Kaitlin M. Kestenberg-Messina sold $158k of ADMA
COO and SVP, Compliance at ADMA BIOLOGICS, INC.. 10,096 shares at an average of $15.63, traded Mar 9, 2026, filed Mar 10, 2026.
Score components
- +20RoleCOO
- +11Trade size$158k at market
- 0Share of holdings soldSold 2.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -37.2%, 3m -48.7%, 6m -39.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-26-008905, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 6, 2026 | FTax withholding Common Stock | -10,059 | $15.39 | $155k | 562,101 | Mar 10, 2026 |
| Mar 7, 2026 | FTax withholding Common Stock | -4,235 | $15.39 | $65k | 557,866 | Mar 10, 2026 |
| Mar 9, 2026 | JOther Common Stock | -91,266 | $0.00 | $0 | 466,600 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock | +2,500 | $5.00 | $13k | 469,100 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock | +1,250 | $4.31 | $5,388 | 470,350 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock | +2,646 | $2.83 | $7,488 | 472,996 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock | +1,525 | $2.35 | $3,584 | 474,521 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Common Stock | +2,175 | $1.55 | $3,371 | 476,696 | Mar 10, 2026 |
| Mar 9, 2026 | SOpen-market sale Common Stock | -10,096 | $15.63 | $158k | 466,600 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Stock Option (right to buy)derivative | -2,500 | $0.00 | $0 | 2,500 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Stock Option (right to buy)derivative | -1,250 | $0.00 | $0 | 1,250 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Stock Option (right to buy)derivative | -2,646 | $0.00 | $0 | 2,771 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Stock Option (right to buy)derivative | -1,525 | $0.00 | $0 | 2,225 | Mar 10, 2026 |
| Mar 9, 2026 | MOption exercise Stock Option (right to buy)derivative | -2,175 | $0.00 | $0 | 2,825 | Mar 10, 2026 |
Related signals
Other insiders at ADMA BIOLOGICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ADMAbuy ADMA BIOLOGICS, INC. | Jerrold B Grossman director | $51k 6,400 shares | +1% | |
| 48Moderate | ADMAbuy ADMA BIOLOGICS, INC. | Jerrold B Grossman director | $100k 12,500 shares | +2% | |
| 43Moderate | ADMAbuy ADMA BIOLOGICS, INC. | Jerrold B Grossman director | $100k 12,500 shares | +3% | |
| 12Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $318k 21,000 shares | -1% | |
| 30Weak | ADMAbuy ADMA BIOLOGICS, INC. | Steve Elms director | $217k 14,000 shares | +1% | |
| 5Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $338k 21,000 shares | -1% | |
| 6Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $416k 21,000 shares | -1% | |
| 5Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $336k 21,000 shares | -1% | |
| 5Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $336k 21,000 shares | -1% | |
| 5Weak | ADMA BIOLOGICS, INC. | Adam S Grossman President and CEO | $339k 21,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.